Viroclinics Biosciences expands with Clinical Trial Operations Services
To provide better support for the pharmaceutical, biotechnology, and medical device industries, Viroclinics has started a specialized group for clinical trial operations.
To provide better support for the pharmaceutical, biotechnology, and medical device industries, Viroclinics has started a specialized group for clinical trial operations. Activities involve preparation of virology sampling kits, on-site sampling handling instruction, courier transport, sample tracking and tracing, and management of sample processing labs. For a smooth logistical flow of samples from all over the globe, Viroclinics works together with sites in Europe, Russia, Ukraine, Australia, New Zealand, USA, Canada, Mexico, Central America region (e.g., Guatemala, El Salvador), South America (Brazil, Argentina, Colombia, Peru, Chile) and South Africa.
The company is demonstrating its sample kits at the InfectiousDisease Week 2013 conference this week in San Francisco.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
